Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. Show more

Location: 321 Arsenal Street, Watertown, MA, 02472, United States | Website: https://www.discmedicine.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.223B

52 Wk Range

$30.82 - $95.95

Previous Close

$86.22

Open

$86.94

Volume

524,181

Day Range

$83.40 - $87.50

Enterprise Value

1.671B

Cash

650M

Avg Qtr Burn

-33.56M

Insider Ownership

8.50%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bitopertin Details erythropoietic porphyrias (EPP), X-linked protoporphyria	NDA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DISC-3405 (formerly MWTX-003) Details Polycythemia vera	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DISC-0974 Details Myelofibrosis, Anemia Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bitopertin Details Anemia, Rare genetic disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DISC-0974 Details Anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GEM103 Details Age-related macular degeneration	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GEM103 Details Wet age-related macular degeneration , Age-related macular degeneration	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.